Citigroup
ENTA icon

Citigroup’s Enanta Pharmaceuticals ENTA Stock Holding History

Citigroup’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.2K Buy
2,077
+655
+46% +$8.78K ﹤0.01% 4753
2025
Q4 		$22.4K Sell
1,422
-680
-32% -$8.64K ﹤0.01% 4830
2025
Q3 		$25.2K Sell
2,102
-7,240
-77% -$57.9K ﹤0.01% 4740
2025
Q2 		$70.6K Sell
9,342
-5,226
-36% -$31.4K ﹤0.01% 4585
2025
Q1 		$80.4K Sell
14,568
-959
-6% -$5.92K ﹤0.01% 4709
2024
Q4 		$89.3K Buy
15,527
+850
+6% +$8.15K ﹤0.01% 4897
2024
Q3 		$152K Buy
14,677
+10,119
+222% +$132K ﹤0.01% 4541
2024
Q2 		$59.1K Buy
4,558
+734
+19% +$9.91K ﹤0.01% 4488
2024
Q1 		$66.8K Buy
3,824
+991
+35% +$13.1K ﹤0.01% 4485
2023
Q4 		$26.7K Buy
2,833
+2,286
+418% +$21.3K ﹤0.01% 4866
2023
Q3 		$6.11K Sell
547
-39,683
-99% -$639K ﹤0.01% 4672
2023
Q2 		$861K Sell
40,230
-10,190
-20% -$300K ﹤0.01% 2959
2023
Q1 		$2.04M Buy
50,420
+1,860
+4% +$88.8K ﹤0.01% 2011
2022
Q4 		$2.26M Sell
48,560
-21,634
-31% -$986K ﹤0.01% 1944
2022
Q3 		$3.64M Buy
70,194
+4,444
+7% +$260K ﹤0.01% 1734
2022
Q2 		$3.11M Buy
65,750
+37,249
+131% +$2.02M ﹤0.01% 1796
2022
Q1 		$2.03M Sell
28,501
-24,797
-47% -$1.61M ﹤0.01% 2340
2021
Q4 		$3.99M Buy
53,298
+26,691
+100% +$2.09M ﹤0.01% 2013
2021
Q3 		$1.51M Sell
26,607
-21,441
-45% -$1.06M ﹤0.01% 2759
2021
Q2 		$2.12M Sell
48,048
-14,040
-23% -$688K ﹤0.01% 2627
2021
Q1 		$3.06M Buy
62,088
+10,551
+20% +$526K ﹤0.01% 2189
2020
Q4 		$2.17M Buy
51,537
+669
+1% +$29.4K ﹤0.01% 2776
2020
Q3 		$2.33M Buy
50,868
+29,280
+136% +$1.42M ﹤0.01% 2513
2020
Q2 		$1.08M Buy
21,588
+4,819
+29% +$249K ﹤0.01% 3477
2020
Q1 		$862K Sell
16,769
-13,842
-45% -$738K ﹤0.01% 3340
2019
Q4 		$1.89M Sell
30,611
-7,954
-21% -$493K ﹤0.01% 3044
2019
Q3 		$2.32M Buy
38,565
+10,545
+38% +$783K ﹤0.01% 2701
2019
Q2 		$2.37M Buy
28,020
+14,959
+115% +$1.35M ﹤0.01% 2669
2019
Q1 		$1.25M Sell
13,061
-56,434
-81% -$5.06M ﹤0.01% 3168
2018
Q4 		$4.92M Buy
69,495
+62,367
+875% +$4.78M 0.01% 1827
2018
Q3 		$609K Buy
7,128
+6,970
+4,411% +$698K ﹤0.01% 4041
2018
Q2 		$18K Sell
158
-19,469
-99% -$1.94M ﹤0.01% 6965
2018
Q1 		$1.59M Sell
19,627
-3,246
-14% -$250K ﹤0.01% 2811
2017
Q4 		$1.34M Sell
22,873
-1,609
-7% -$80.6K ﹤0.01% 3042
2017
Q3 		$1.15M Sell
24,482
-6,033
-20% -$243K ﹤0.01% 3226
2017
Q2 		$1.1M Buy
30,515
+4,521
+17% +$145K ﹤0.01% 3206
2017
Q1 		$800K Sell
25,994
-24,460
-48% -$762K ﹤0.01% 3447
2016
Q4 		$1.69M Buy
50,454
+32,822
+186% +$941K ﹤0.01% 3133
2016
Q3 		$469K Buy
17,632
+9,248
+110% +$215K ﹤0.01% 3946
2016
Q2 		$184K Sell
8,384
-4,933
-37% -$129K ﹤0.01% 4575
2016
Q1 		$391K Buy
13,317
+10,552
+382% +$294K ﹤0.01% 4399
2015
Q4 		$92K Sell
2,765
-6,854
-71% -$223K ﹤0.01% 5436
2015
Q3 		$348K Buy
9,619
+2,367
+33% +$102K ﹤0.01% 4069
2015
Q2 		$326K Buy
7,252
+178
+3% +$6.92K ﹤0.01% 4068
2015
Q1 		$217K Buy
7,074
+87
+1% +$3.38K ﹤0.01% 4454
2014
Q4 		$356K Buy
6,987
+5,614
+409% +$251K ﹤0.01% 4200
2014
Q3 		$54K Buy
1,373
+464
+51% +$18.5K ﹤0.01% 5261
2014
Q2 		$39K Buy
909
+312
+52% +$11.9K ﹤0.01% 5328
2014
Q1 		$23K Sell
597
-744
-55% -$27K ﹤0.01% 5944
2013
Q4 		$37K Buy
1,341
+1,335
+22,250% +$32.4K ﹤0.01% 5864
2013
Q3 		$0 Buy
6
+1
+20% +$19 ﹤0.01% 6835
2013
Q2 		$0 Buy
+5
New +$97 ﹤0.01% 6752

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citigroup's ENTA Position: Q1 2026 in Review

Citigroup increased its Enanta Pharmaceuticals (ENTA) stake by 46% in Q1 2026, buying an estimated $8.78K and bringing the position to 2,077 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4753.

Citigroup first reported a position in ENTA in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.92M in Q4 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Citigroup held 2,077 shares of Enanta Pharmaceuticals worth $26.2K as of Q1 2026.
  • Citigroup bought 655 Enanta Pharmaceuticals shares in Q1 2026, an estimated $8.78K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4753 holding.
  • Citigroup first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Enanta Pharmaceuticals position peaked at $4.92M in Q4 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.